Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chakrabarti, Gaurab ^a,b   Silvers, Molly A ^a,b   Ilcheva, Mariya ^b   Liu, Yuliang ^a,b   Moore, Zachary R ^a,b   Luo, Xiuquan ^a,b   Gao, Jinming ^a   Anderson, Glenda ^c   Liu, Lili ^d   Sarode, Venetia ^e   Gerber, David E ^b   Burma, Sandeep ^b   DeBerardinis, Ralph J ^f   Gerson, Stanton L ^d   Boothman, David A ^a,b  

^a UT Southwestern   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Degrees Bio   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA-LAPACHONE; CATALASE; DICOUMAROL; DNA BINDING PROTEIN; DNA GLYCOSYLTRANSFERASE; HYDROXYLAMINE; METHOXYAMINE; NAPHTHOQUINONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NQO1 PROTEIN, HUMAN; OXOGUANINE GLYCOSYLASE 1, HUMAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOPHAGY; CELL SURVIVAL; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; AUTOPHAGY; CATALASE; CELL LINE, TUMOR; CELL SURVIVAL; DICUMAROL; DNA BREAKS, DOUBLE-STRANDED; DNA GLYCOSYLASES; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYDROXYLAMINES; MICE; MICE, NUDE; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84948171903     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17066     Document Type: Article

References (58)

1. ACS. Cancer Facts and Figures 2014. Atlanta: American Cancer Society (2014).
2. Maginn, E. N., de Sousa, C. H., Wasan, H. S. & Stronach, E. A. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer. Biochimica et biophysica acta 1846, 45-54 (2014).
3. Awadallah, N. S. et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry 16, 24-31 (2008).
4. Glen, V. L., Hutson, P. R., Kehrli, N. J., Boothman, D. A. & Wilding, G. Quantitation of beta-lapachone and 3-hydroxy-beta-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications 692, 181-186 (1997).
5. Pink, J. J. et al. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. The Journal of biological chemistry 275, 5416-5424 (2000).
6. Bey, E. A. et al. Catalase abrogates beta-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Molecular cancer therapeutics 12, 2110-2120 (2013).
7. Tagliarino, C., Pink, J. J., Dubyak, G. R., Nieminen, A. L. & Boothman, D. A. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. The Journal of biological chemistry 276, 19150-19159 (2001).
8. Moore, Z. et al. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by beta-lapachone. Cell death & disease 6, e1599 (2015).
9. Bentle, M. S., Reinicke, K. E., Dong, Y., Bey, E. A. & Boothman, D. A. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer research 67, 6936-6945 (2007).
10. L. P. Hartner et al. Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS). Journal of Clinical Oncology (2007).
11. Zong, W. X., Ditsworth, D., Bauer, D. E., Wang, Z. Q. & Thompson, C. B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes & Development 18, 1272-1282 (2004).
12. Yu, S. W. et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297, 259-263 (2002).
13. Li, L. S. et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. Clinical cancer research: an official journal of the American Association for Cancer Research 17, 275-285 (2011).
14. Prasad, R. et al. Suicidal cross-linking of PARP-1 to AP site intermediates in cells undergoing base excision repair. Nucleic acids research 42, 6337-6351 (2014).
15. Campalans, A. et al. Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair. Nucleic acids research 41, 3115-3129 (2013).
16. Khodyreva, S. N. et al. Apurinic/apyrimidinic (AP) site recognition by the 5′-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1). Proceedings of the National Academy of Sciences of the United States of America 107, 22090-22095 (2010).
17. Dianov, G. L. & Hubscher, U. Mammalian base excision repair: the forgotten archangel. Nucleic acids research 41, 3483-3490 (2013).
18. Guzy, R. D. & Schumacker, P. T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Experimental physiology 91, 807-819 (2006).
19. Krokan, H. E. & Bjoras, M. Base excision repair. Cold Spring Harbor perspectives in biology 5, a012583 (2013).
20. Bruner, S. D., Norman, D. P. & Verdine, G. L. Structural basis for recognition and repair of the endogenous mutagen 8-oxoguanine in DNA. Nature 403, 859-866 (2000).
21. El-Khamisy, S. F., Masutani, M., Suzuki, H. & Caldecott, K. W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic acids research 31, 5526-5533 (2003).
22. Boiteux, S. & Guillet, M. Abasic sites in DNA: repair and biological consequences in Saccharomyces cerevisiae. DNA repair 3, 1-12 (2004).
23. Izumi, T. et al. Mammalian DNA base excision repair proteins: their interactions and role in repair of oxidative DNA damage. Toxicology 193, 43-65 (2003).
24. Almeida, K. H. & Sobol, R. W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA repair 6, 695-711 (2007).
25. Horton, J. K. et al. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses. DNA repair 12, 774-785 (2013).
26. Cao, L. et al. Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs in Triple-Negative Breast Cancers. Antioxidants & redox signaling 21, 237-250 (2014).
27. Bentle, M. S., Reinicke, K. E., Bey, E. A., Spitz, D. R. & Boothman, D. A. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. The Journal of biological chemistry 281, 33684-33696 (2006).
28. Bey, E. A. et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proceedings of the National Academy of Sciences of the United States of America 104, 11832-11837 (2007).
29. Huang, X. et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer research 72, 3038-3047 (2013).
30. Bey, E. A. et al. Catalase abrogates beta-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Molecular cancer therapeutics 12, 2110-2120 (2013).
31. Dong, Y. et al. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer research 70, 8088-8096 (2010).
32. Gartner, E. M., Burger, A. M. & Lorusso, P. M. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer journal 16, 83-90 (2010).
33. Mahjabeen, I., Ali, K., Zhou, X. & Kayani, M. A. Deregulation of base excision repair gene expression and enhanced proliferation in head and neck squamous cell carcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35, 5971-5983 (2014).
34. Mahjabeen, I., Chen, Z., Zhou, X. & Kayani, M. A. Decreased mRNA expression levels of base excision repair (BER) pathway genes is associated with enhanced Ki-67 expression in HNSCC. Medical oncology 29, 3620-3625 (2012).
35. Vaezi, A., Feldman, C. H. & Niedernhofer, L. J. ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer. Pharmacogenomics and personalized medicine 4, 47-63 (2011).
36. Zhang, G. et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PloS one 7, e31507 (2012).
37. Yan, L. et al. Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha. Clinical cancer research : an official journal of the American Association for Cancer Research 13, 1532-1539 (2007).
38. Guerreiro, P. S. et al. Differential effects of methoxyamine on doxorubicin cytotoxicity and genotoxicity in MDA-MB-231 human breast cancer cells. Mutation research 757, 140-147 (2013).
39. Montaldi, A. P. & Sakamoto-Hojo, E. T. Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide. Clinical and experimental medicine 13, 279-288 (2013).
40. Fishel, M. L., He, Y., Smith, M. L. & Kelley, M. R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clinical cancer research : an official journal of the American Association for Cancer Research 13, 260-267 (2007).
41. Liu, L. & Gerson, S. L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Current opinion in investigational drugs 5, 623-627 (2004).
42. Liu, L., Nakatsuru, Y. & Gerson, S. L. Base excision repair as a therapeutic target in colon cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 8, 2985-2991 (2002).
43. + depletion. Cell reports 8, 1819-1831 (2014).
44. Jelezcova, E. et al. Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage. Mutation research 686, 57-67 (2010).
45. Fu, D., Jordan, J. J. & Samson, L. D. Human ALKBH7 is required for alkylation and oxidation-induced programmed necrosis. Genes & Development 27, 1089-1100 (2013).
46. Andrabi, S. A. et al. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proceedings of the National Academy of Sciences of the United States of America 111, 10209-10214 (2014).
47. Blanco, E. et al. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer research 70, 3896-3904 (2010).
48. D. Gerber et al. Phase 1 correlative study of ARQ761, a b-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis. European journal of cancer 50 (2014).
49. Thapa, D. et al. NQO1 suppresses NF-kappaB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer research 74, 5644-5655 (2014).
50. Choi, E. K. et al. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 9, 634-642 (2007).
51. Ahn, K. S., Sethi, G., Jain, A. K., Jaiswal, A. K. & Aggarwal, B. B. Genetic deletion of NAD(P)H:quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. The Journal of biological chemistry 281, 19798-19808 (2006).
52. Kim, I. K., Stegeman, R. A., Brosey, C. A. & Ellenberger, T. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADPribose) glycohydrolase. The Journal of biological chemistry 290, 3775-3783 (2015).
53. Oka, S. et al. Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAs. The EMBO journal 27, 421-432 (2008).
54. Noren Hooten, N., Kompaniez, K., Barnes, J., Lohani, A. & Evans, M. K. Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1). The Journal of biological chemistry 286, 44679-44690 (2011).
55. Savage, R. E. et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ARQ 501 (beta-lapachone) in plasma and tumors from nu/nu mouse xenografts. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 872, 148-153 (2008).
56. P. Caimi et al. Phase I Trial of the Base - Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies. Blood 124 (2014).
57. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
58. Robinson, M. D. & Speed, T. P. A comparison of Affymetrix gene expression arrays. BMC bioinformatics 8, 449 (2007).